GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP4) inhibitors, which prevent the degradation of endogenous GLP-1, are widely used in the treatment of type 2 diabetes [28,29,30]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.